HDAC9 and T-cell non-Hodgkin lymphoma: No clinical trials yet, requires rigorous pre-clinical and clinical validation. Already FDA approved for T-cell lymphoma. As Vorinostat is an HDAC inhibitor off-target effects, including cardiac effects, can be an issue [216].